Curex Review
Semaglutide & tirzepatide GLP-1 weight-loss telehealth · Independently scored 7.9/10
Best for: an oral route if you will not self-inject
Curex falls below our bar on medical oversight. Read the breakdown below before you give it money.
then $199/mo ongoing
Covered by the monthly price
Medication
In the price
Clinician visits
In the price
Shipping
In the price
Lab work
Charged on top
Coaching
Not stated
No insurance needed · Vetted by our editors
Curex, Inc. sells compounded semaglutide at $149/mo and compounded tirzepatide at $199/mo, in injectable and oral dissolving tablet formats. It is LegitScript certified, charges no membership fee and is available in 43+ states. Offices are in Miami and New York City. The company started out in allergy immunotherapy.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Vetted alternatives to Curex
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Curex at a glance
- Type
- GLP-1 telehealth provider
- Medications
- Semaglutide, Tirzepatide
- Starting price
- $49/mo (ongoing anchored only as 'From $199/mo'; per-drug standard price no longer separately displayed; $49 = Summer Sale fi...)
- What's included
- Medication · Consult · Shipping
- Availability
- 45 states
- FDA status
- 1 FDA warning letter on record — see below
How Curex scores
Six columns, each one computed from something Curex has published rather than from an opinion we formed: what it charges, which molecules it will dispense, what its record shows, and what the monthly figure actually buys. Where it publishes nothing, that absence is what gets scored. Every seller in the register goes through the same six columns.
Value25%
7.1/10$199/month is 25% below the register median of $267 for compounded tirzepatide.
Effectiveness25%
10.0/10Dispenses semaglutide and tirzepatide, compounded only. Anchored to SURMOUNT-1 (tirzepatide, -20.9%) and STEP 1 (semaglutide, -14.9%).
User Experience15%
8.0/10On the seller's own pages, a price is published before the questionnaire starts.
Trust & Safety15%
5.5/101 FDA warning letter on record; does not name a dispensing pharmacy; shows a price before asking for health information; publishes its state list. Our verification confidence is high.
Accessibility10%
9.2/10Publishes coverage in 45 of 50 states.
Support10%
7.0/10The price covers medication, consult, shipping.
A seller that will not show a price before an intake loses points on Value and carries that note in its review. Withholding the number is itself a finding. How we score →
What we checked on Curex
Last checked August 2026- Re-read the price on file across 2 dose or plan tiers
- Checked state coverage: all 50
- Established what the monthly figure covers, and what it leaves out
- Searched our FDA enforcement register for this operator
Price, availability, and compliance here are read off the seller's own pages and off primary regulatory records, named in the sources below. Editorial confidence in this data: high.
What signing up with Curex involves
Assembled from this seller’s entry in the register — the price record, the state list, the dispensing pharmacy where one is named, and what the monthly figure covers. It describes what a reader can expect to meet on the way to a prescription, and what is missing from the seller’s own disclosures. It is not a clinical judgment and not a prescribing decision.
- 1Curex publishes a price on its own site before asking anything about you. You can compare it against this register without starting a questionnaire.
- 2The intake is a written questionnaire. No live video visit or baseline bloodwork is recorded as required.
- 3Curex does not say which pharmacy dispenses the medication. That is common here and it means you cannot check the pharmacy's record before you buy.
- 4The monthly price is recorded as covering medication, consult, shipping.
- Cheapest standing monthly prices on record: semaglutide $199, tirzepatide $199. Membership fees, first-month rates and insured copays are excluded from those figures.
- Coverage is published for 45 of 50 states.
- 1 FDA warning letter on record. The letter itself is linked in the enforcement section below — read what it alleges rather than the fact that it exists.
- The medication is compounded, so it is not an FDA-approved product and has not been reviewed by the agency for safety, effectiveness or manufacturing quality.
Curex support, as documented
- Phone
- (857) 240-1080
- hi@getcurex.com
GLP-1 medications Curex offers
Each one has its own guide: how the molecule works, the dosing schedule, the side effects that show up in practice, and what the trials actually measured.
Pricing
Prices re-verified
ongoing anchored only as 'From $199/mo'; per-drug standard price no longer separately displayed; $49 = Summer Sale first month
ongoing anchored only as 'From $199/mo'; per-drug standard price no longer separately displayed; $149 = Summer Sale first month
Check the price yourself before you pay
Every figure here was read off Curex's own checkout on the date shown. Sellers move prices without announcing it, and promotional rates lapse, so confirm the standing cost on their site before committing.
In its favor
- Semaglutide at $199 a month, within the normal band around this register's $189 median for the same drug and form
- Publishes a price on its own site before the medical questionnaire, so it can be compared without handing over health information
- The monthly figure covers medication, consult, shipping
- Coverage is published for 45 states
Against it
- Billed separately from the monthly figure: labs
- No dispensing pharmacy is named in our record, so its accreditation cannot be looked up from here
- 1 FDA warning letter matched to this operator in our enforcement register — read what the letter alleges, since a letter discloses a problem rather than disqualifying a seller
- Its semaglutide and tirzepatide are compounded rather than FDA-approved, so they have not been reviewed by the agency for safety, effectiveness or manufacturing quality
What Curex charges
The figure Curex leads with is $49, and it is a first-month rate. From month two the price is $199/month, which is the number to plan around. Nothing improper about an introductory offer — it just is not the price of staying on the medication.
- Compounded semaglutide — $49 first month, then $199/month
- Compounded tirzepatide — $149 first month, then $199/month
The median standing price across the GLP-1 providers we track is about $169/month, so this is a premium, and a premium has to buy something. Discounting the first month does not change the twelve-month total by much.
Found dispenses semaglutide and tirzepatide from $149/month, which makes it the honest comparison to run before committing here.
What Curex dispenses
Curex prescribes semaglutide (approved as Wegovy and Ozempic) and tirzepatide (approved as Zepbound and Mounjaro). Between them these are the two best-evidenced weight-loss molecules currently on the market. The medication is compounded rather than dispensed as an approved pen. Compounding serves real clinical needs and is entirely lawful; what it is not is reviewed, and the cost difference reflects that.
A needle-free oral option is genuinely uncommon and is the reason some readers will look at Curex at all. Set expectations on the evidence, though: the published weight-loss trials for these molecules used injections. Oral and sublingual delivery of peptides is far less studied, so treat it as a route that solves the needle problem rather than as a demonstrated equal to the shot.
What we could verify
On the record: it treats patients in all 50 states. FDA has sent this operator a warning letter, and we flag it at the top of the page. A letter is a disclosure, not a disqualification: read what it actually says before deciding what it means for you. Because the medication is compounded and no dispensing pharmacy is named publicly, the single most useful question to ask at intake is which licensed pharmacy fills the prescription. A seller that will not answer that has told you something. How we weigh oversight, disclosure and price evidence is set out in our scoring methodology.
Who should look elsewhere
- You are optimizing for the twelve-month total rather than the first bill — a flat-rate seller such as CoreAge Rx will usually win that arithmetic.
- You would be choosing on the advertised figure. The introductory month is real, but it is not what you will be paying in month three.
- You want the FDA-approved pen specifically. Nothing here is the approved finished product.
- You need to bill insurance. Like most of this market, this is cash-pay.
- A regulatory record matters to you more than price does — read the warning letter flagged above before deciding.
It fits if
- you want a cheap way to find out whether the medication suits you before committing
- injections are the thing keeping you from starting
- you need access regardless of where you live
Our read
Curex is a cheap way to start and an ordinary way to continue. Use the $49 month for what it is good for — establishing whether the medication works for you — and re-run the numbers against $199/month before you let it renew twice. Breeze Meds is the nearest comparison we track, and worth reading alongside this. Whatever you decide, read the warning letter flagged at the top of this page first, and raise it with the clinician you would be prescribing through.
The Bottom Line
Curex falls below our bar on medical oversight. Read the breakdown below before you give it money.
Before you pay Curex
Starting at $49/month. Check today's price, then book the free consultation.
Where Curex is the wrong choice
No seller in this register suits every reader, and saying otherwise would be the easiest way to sell one. On these four counts another entry does better.
Frequently Asked Questions
Glossary
The words sellers use, defined. Tap any term.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Regulatory notice
Curex has an FDA warning letter on record, dated September 9, 2025
This letter concerns unlawful sale of unapproved and misbranded drugs to united states consumers over the internet (telehealth). A warning letter is public correspondence from FDA, not an adjudication. On its own it establishes no finding of illegal activity, and a company that gets one often answers with corrective action.
Sources
Cited across this Curex review: primary regulatory filings, and peer-reviewed studies.
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
See Curex's current pricing
Plans start at $49/month. The free consultation is where you learn whether you qualify, and what it costs today.